FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class Marco Meglio

Published Date: 16 Nov 2026

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New Immune Therapy Boosts Disease Control in Prostate Cancer

2.

Talquetamab Regimens Boost Survival in Multiple Myeloma

3.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

4.

Alternative breast imaging techniques beyond mammography.

5.

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot